Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.
Maze Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know
Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider lock-up period of 180 days ending on July 30, 2025.
Drug developer Maze Therapeutics eyes up to $728 million valuation in US IPO
and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Maze, backed by healthcare venture firms ARCH Venture and Third Rock Ventures, as well as ...
Biotech firm Maze Therapeutics raises $140 million in US IPO
Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech listing this year.
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
Obesity drug developer Metsera sets terms for $275M IPO
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR) said it was looking to offer 17.
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO
Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such treatments.
FierceBiotech3d
Maze rolls out map to $131M IPO, as phase 2 kidney disease trial readies for dosing
Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...
Seeking Alpha17d
Maze Therapeutics Seeks IPO For Trials Ramp-Up
A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The ...
MarketWatch23d
Maze Therapeutics Files for IPO
Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...
ENDPOINTS NEWS3d
Maze looks to lead IPO queue with $113M Nas­daq de­but
Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...
The Pharma Letter2d
Three biotechs go public as IPO momentum increases
The biotech IPO landscape gains momentum in 2025 as Aurion Biotech, Maze Therapeutics, and Metsera file for offerings. Aurion focuses on regenerative therapies, Maze advances precision medicines for ...
pharmaphorum9d
Two more biotechs join IPO waiting list
Formed in 2019, Sionna's most recent financing was a $182 million third round that closed last year, which followed a $111 ...